Enlivex announced positive 12-month topline data from its Phase IIa trial for Allocetra™ in knee osteoarthritis, showing a significantly higher responder rate compared to placebo. This favorable clinical trial outcome is a major positive catalyst for the company, validating its immunotherapy candidate for inflammatory conditions.
Enlivex Ltd. reported favorable 12-month topline data from its Phase IIa clinical trial for Allocetra™ in moderate to severe knee osteoarthritis. The study showed a statistically significant improvement in responder rates for the Allocetra™ group compared to placebo (79.2% vs. 47.6%, p=0.027), consistent with earlier observations. This positive clinical outcome is a significant validation for Enlivex's lead immunotherapy candidate, potentially accelerating its development and increasing its market value. For traders, this represents a strong short-term opportunity for ENLV stock due to increased investor confidence and long-term potential if subsequent trials continue to be successful, positioning the company as a key player in inflammatory disease treatment.